Infinity Beneish M Score

INFI -  USA Stock  

USD 2.29  0.20  9.57%

This module uses fundamental data of Infinity Pharmaceuti to approximate the value of its Beneish M Score. Infinity Pharmaceuti M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Please see Infinity Pharmaceuti Piotroski F Score and Infinity Pharmaceuti Altman Z Score analysis.

Infinity Beneish M Score 

 
Refresh
Infinity Pharmaceuti Debt Non Current is most likely to decrease significantly in the upcoming years. The last year's value of Debt Non Current was reported at 1.44 Million. Infinity Pharmaceuti Accrued Expenses Turnover is most likely to drop in the upcoming years. The last year's value of Accrued Expenses Turnover was reported at 0.24. The current Cash and Equivalents Turnover is estimated to increase to 0.07, while Operating Margin is projected to decrease to (52.31) .
At this time, it appears that Infinity Pharmaceuti is an unlikely manipulator. The earnings manipulation may begin if Infinity Pharmaceuti's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Infinity Pharmaceuti executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Infinity Pharmaceuti's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.88
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables
0.97
Asset Quality
1.0
Expense Coverage
1.33
Gross Margin Strengs
0.99
Accruals Factor
1.33
Depreciation Resistance
1.0
Net Sales Growth
1.03
Financial Leverage Condition
0.97

Infinity Pharmaceuti Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Infinity Pharmaceuti's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Revenues1.8 M1.7 M
Fairly Up
Decreasing
Slightly volatile
Selling General and Administrative Expense16.9 M12.4 M
Significantly Up
Decreasing
Slightly volatile
Net Cash Flow from Operations(38.6 M)(35.7 M)
Significantly Down
Increasing
Very volatile
Depreciation Amortization and Accretion495.7 K483 K
Fairly Up
Decreasing
Slightly volatile
Total Assets40.4 M39.3 M
Fairly Up
Decreasing
Slightly volatile
Investments5.8 M5.7 M
Fairly Up
Decreasing
Slightly volatile
Investments Current5.7 M5.5 M
Fairly Up
Decreasing
Slightly volatile
Investments Non Current169.3 K165 K
Fairly Up
Decreasing
Slightly volatile
Property Plant and Equipment Net3.2 M3.1 M
Fairly Up
Decreasing
Stable
Trade and Non Trade Receivables2.1 M2.1 M
Slightly Down
Increasing
Stable
Total Liabilities61.7 M62.3 M
Slightly Down
Decreasing
Stable
Current Assets37 M36 M
Fairly Up
Decreasing
Slightly volatile
Assets Non Current3.4 M3.3 M
Fairly Up
Decreasing
Slightly volatile
Current Liabilities16.8 M11 M
Way Up
Decreasing
Slightly volatile
Liabilities Non Current44.9 M51.3 M
Fairly Down
Decreasing
Stable
Total Debt1.5 M1.4 M
Fairly Up
Decreasing
Slightly volatile
Debt Current7.4 M6.9 M
Significantly Up
Increasing
Slightly volatile
Debt Non Current1.5 M1.4 M
Fairly Up
Decreasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile

Infinity Pharmaceuti Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Infinity Pharmaceuti's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Infinity Pharmaceuti in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Infinity Pharmaceuti's degree of accounting gimmicks and manipulations.

About Infinity Pharmaceuti Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation Amortization and Accretion

495,711Share
Infinity Pharmaceuti Depreciation Amortization and Accretion is most likely to decrease significantly in the upcoming years. The last year's value of Depreciation Amortization and Accretion was reported at 483,000

Infinity Pharmaceuti Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Infinity Pharmaceuti. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201620172018201920202021 (projected)
Revenues18.72 M6 M22.15 M3.05 M1.72 M1.76 M
Total Assets125.66 M59.35 M60.22 M49.01 M39.32 M40.35 M
Current Assets101.66 M58.39 M59.82 M44.58 M36.02 M36.97 M
Assets Non Current24 M967 K397 K4.43 M3.3 M3.39 M
Total Liabilities43.2 M11.62 M7.76 M41.29 M62.31 M61.7 M
Current Liabilities23.86 M11.6 M7.72 M9.7 M11.05 M16.78 M
Operating Income(30.89 M)(36.45 M)(11.93 M)(45.66 M)(38.5 M)(41.54 M)
Investments18.53 M23 M9.97 M20.5 M5.68 M5.83 M
Investments Current18 M23 M9.97 M20.18 M5.51 M5.66 M

About Infinity Pharmaceuti Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Infinity Pharmaceuti's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Infinity Pharmaceuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Infinity Pharmaceuti based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 11b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta andor gamma isoforms of PI3K Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Infinity Pharmaceuti without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Infinity Pharmaceuti using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Infinity Pharmaceuti Piotroski F Score and Infinity Pharmaceuti Altman Z Score analysis. Note that the Infinity Pharmaceuti information on this page should be used as a complementary analysis to other Infinity Pharmaceuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for activelly traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Infinity Stock analysis

When running Infinity Pharmaceuti price analysis, check to measure Infinity Pharmaceuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infinity Pharmaceuti is operating at the current time. Most of Infinity Pharmaceuti's value examination focuses on studying past and present price action to predict the probability of Infinity Pharmaceuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Infinity Pharmaceuti's price. Additionally, you may evaluate how the addition of Infinity Pharmaceuti to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Is Infinity Pharmaceuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Infinity Pharmaceuti. If investors know Infinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Infinity Pharmaceuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Infinity Pharmaceuti is measured differently than its book value, which is the value of Infinity that is recorded on the company's balance sheet. Investors also form their own opinion of Infinity Pharmaceuti's value that differs from its market value or its book value, called intrinsic value, which is Infinity Pharmaceuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Infinity Pharmaceuti's market value can be influenced by many factors that don't directly affect Infinity Pharmaceuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Infinity Pharmaceuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Infinity Pharmaceuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Infinity Pharmaceuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.